Everolimus as second-line treatment in metastatic renal cell carcinoma (mRCC) after first-line pazopanib (The RESCUE study): A retrospective analysis by the Hellenic GU Cancer Group (HGUCG) with international collaboration.

Abstract

e15601 Background: Pazopanib and everolimus are approved first and second line therapies in mRCC, respectively. However, real-world data on the efficacy and safety of everolimus as second-line trea...